{"text_format":"1","workbook":"xlsx","n_sheets":3,"sheets":["Cover sheet","Introduction","Data sheet"],"not_rendered":{"charts":0,"images":1,"macros":1,"external_links":0,"defined_names":179,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Cover sheet","index":0,"n_rows":0,"n_cols":0,"rows_kept":0,"cut":false,"hidden":false,"merged":[]}

{"sheet":"Introduction","index":1,"n_rows":23,"n_cols":2,"rows_kept":23,"cut":false,"hidden":false,"merged":[]}
[null,"Baseline assessment tool for ulcerative colitis: management  (NICE clinical guideline NG130)"]
[]
[null,"This baseline assessment tool can be used to evaluate whether practice is in line with the recommendations in Ulcerative colitis: management .  It can also help to plan activity to meet the recommendations."]
[]
[null,"The tool can be used by individual services or organisations. Alternatively, an assessment completed with the involvement of all relevant services or organisations would help to develop a picture of activity in the local area."]
[]
[null,"It should be used in conjunction with Ulcerative colitis: management (NICE clinical guideline NG130)."]
[]
[null,"In the first instance, consider whether the guideline is relevant and record the conclusion in the box below."]
[]
[null,"Is the guideline relevant?"]
[]
[]
[null,"The data sheet contains the recommendations from the guideline. Information can be entered about current activity relevant to the recommendation, actions needed to meet the recommendation, deadlines and the names of the responsible leads.  Useful documents can be added as hyperlinks."]
[]
[null,"The table can be adapted to include any other local information that is thought to be useful."]
[]
[null,"If it would be helpful to group the recommendations, for example those that are key priorities for implementation or by deadline, use the filter function in the data menu. "]
[]
[null,"Tools and resources to help put the guidance into practice are available on the NICE website. "]
[]
[]
[null,"National Institute for Health and Care Excellence\nLevel 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT; www.nice.org.uk\n\nCopyright\n© NICE 2019. All rights reserved. Subject to Notice of rights.\n"]

{"sheet":"Data sheet","index":2,"n_rows":80,"n_cols":12,"rows_kept":80,"cut":false,"hidden":false,"merged":[[0,1,0,11]]}
[null,"Baseline assessment tool for ulcerative colitis: management  (NICE clinical guideline NG130)"]
[]
[null,null,null,null,null,"Number of relevant recommendations",{"$f":"COUNTIF(E8:E995,\"Yes\")","v":0}]
[null,null,null,null,null,"Number of recommendations met",{"$f":"COUNTIF(G8:G995,\"Yes\")","v":0}]
[null,null,null,null,null,"Percentage of recommendations met",{"$f":"IF(ISERROR(G4/G3),\"\",G4/G3)","v":""}]
[]
[null,"NICE recommendation","Guideline reference","Year of recommendation","Is the recommendation relevant?","Current activity/evidence","Recommendation met?","Actions needed to implement recommendation","Is there a risk associated with not implementing this recommendation?","Is there a cost or saving?","Deadline","Lead"]
[null,"1.1  Patient information and support"]
[null,"Discuss the disease and associated symptoms, treatment options and monitoring:\n•\twith the person with ulcerative colitis and their family members or carers (as appropriate) and\n•\twithin the multidisciplinary team (the composition of which should be appropriate for the age of the person) at every opportunity.\nApply the principles in the NICE guideline on patient experience in adult NHS services. ","1.1.1",2013]
[null,"Discuss the possible nature, frequency and severity of side effects of drug treatment for ulcerative colitis with the person, and their family members or carers (as appropriate). Refer to the NICE guideline on medicines adherence. ","1.1.2",2013]
[null,"Give the person, and their family members or carers (as appropriate) information about their risk of developing colorectal cancer and about colonoscopic surveillance, in line with the NICE guidelines on:\n•\tcolorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas  \n•\tsuspected cancer: recognition and referral. ","1.1.3",2013]
[null,"1.2  Inducing remission in people with ulcerative colitis"]
[null,"Treating mild-to-moderate ulcerative colitis"]
[null,"Proctitis"]
[null,"To induce remission in people with a mild-to-moderate first presentation or inflammatory exacerbation of proctitis, offer a topical aminosalicylate as first-line treatment. ","1.2.1",2019]
[null,"If remission is not achieved within 4 weeks, consider adding an oral aminosalicylate. ","1.2.2",2019]
[null,"If further treatment is needed, consider adding a time-limited course of a topical or an oral corticosteroid. ","1.2.3",2019]
[null,"For people who decline a topical aminosalicylate:\n•\tconsider an oral aminosalicylate as first-line treatment, and explain that this is not as effective as a topical aminosalicylate\n•\tif remission is not achieved within 4 weeks, consider adding a time-limited course of a topical or an oral corticosteroid. ","1.2.4",2019]
[null,"For people who cannot tolerate aminosalicylates, consider a time-limited course of a topical or an oral corticosteroid. ","1.2.5",2019]
[null,"Proctosigmoiditis and left-sided ulcerative colitis"]
[null,"To induce remission in people with a mild-to-moderate first presentation or inflammatory exacerbation of proctosigmoiditis or left-sided ulcerative colitis, offer a topical aminosalicylate as first-line treatment. ","1.2.6",2019]
[null,"If remission is not achieved within 4 weeks, consider: \n•\tadding a high-dose oral aminosalicylate to the topical aminosalicylate or \n•\tswitching to a high-dose oral aminosalicylate and a time-limited course of a topical corticosteroid. ","1.2.7",2019]
[null,"If further treatment is needed, stop topical treatments and offer an oral aminosalicylate and a time-limited course of an oral corticosteroid. ","1.2.8",2019]
[null,"For people who decline any topical treatment:\n•\tconsider a high-dose oral aminosalicylate alone, and explain that this is not as effective as a topical aminosalicylate\n•\tif remission is not achieved within 4 weeks, offer a time-limited course of an oral corticosteroid in addition to the high-dose aminosalicylate.","1.2.9",2019]
[null,"For people who cannot tolerate aminosalicylates, consider a time-limited course of a topical or an oral corticosteroid. ","1.2.10",2019]
[null,"Extensive disease"]
[null,"To induce remission in people with a mild-to-moderate first presentation or inflammatory exacerbation of extensive ulcerative colitis, offer a topical aminosalicylate and a high-dose oral aminosalicylate as first-line treatment. ","1.2.11",2019]
[null,"If remission is not achieved within 4 weeks, stop the topical aminosalicylate and offer a high-dose oral aminosalicylate with a time-limited course of an oral corticosteroid. ","1.2.12",2019]
[null,"For people who cannot tolerate aminosalicylates, consider a time-limited course of an oral corticosteroid. ","1.2.13",2019]
[null,"Biologics and Janus kinase inhibitors for moderately to severely active ulcerative colitis: all extents of disease"]
[null,"For guidance on biologics and Janus kinase inhibitors for treating moderately to severely active ulcerative colitis, see the NICE technology appraisal guidance on:\n•\tinfliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis \n•\tvedolizumab for treating moderately to severely active ulcerative colitis \n•\ttofacitinib for moderately to severely active ulcerative colitis. ","1.2.14",2019]
[null,"Treating acute severe ulcerative colitis: all extents of disease"]
[null,"The multidisciplinary team"]
[null,"For people admitted to hospital with acute severe ulcerative colitis:\n•\tensure that a gastroenterologist and a colorectal surgeon collaborate to provide treatment and management\n•\tensure that the composition of the multidisciplinary team is appropriate for the age of the person\n•\tseek advice from a paediatrician with expertise in gastroenterology when treating a child or young person\n•\tensure that the obstetric and gynaecology team is included when treating a pregnant woman. ","1.2.15",2013]
[null,"Step 1 therapy"]
[null,"For people admitted to hospital with acute severe ulcerative colitis (either a first presentation or an inflammatory exacerbation):\n•\toffer intravenous corticosteroids to induce remission and\n•\tassess the likelihood that the person will need surgery (see recommendation 1.2.22). ","1.2.16",2013]
[null,"Consider intravenous ciclosporin or surgery for people:\n•\twho cannot tolerate or who decline intravenous corticosteroids or\n•\tfor whom treatment with intravenous corticosteroids is contraindicated.\nTake into account the person’s preferences when choosing treatment. ","1.2.17",2013]
[null,"Step 2 therapy"]
[null,"Consider adding intravenous ciclosporin to intravenous corticosteroids or consider surgery for people:\n•\twho have little or no improvement within 72 hours of starting intravenous corticosteroids or\n•\twhose symptoms worsen at any time despite corticosteroid treatment.\nTake into account the person’s preferences when choosing treatment. ","1.2.18",2013]
[null,"Infliximab is recommended as an option for the treatment of acute exacerbations of severely active ulcerative colitis only in patients in whom ciclosporin is contraindicated or clinically inappropriate, based on a careful assessment of the risks and benefits of treatment in the individual patient. ","1.2.19",2008]
[null,"In people who do not meet the criterion in 1.2.19, infliximab should only be used for the treatment of acute exacerbations of severely active ulcerative colitis in clinical trials. ","1.2.20",2008]
[null,"Monitoring treatment"]
[null,"Ensure that there are documented local safety monitoring policies and procedures (including audit) for adults, children and young people receiving treatment that needs monitoring (aminosalicylates, tacrolimus, ciclosporin, infliximab, azathioprine and mercaptopurine). Nominate a member of staff to act on abnormal results and communicate with GPs and people with ulcerative colitis and their family members or carers (as appropriate). ","1.2.21",2013]
[null,"Assessing likelihood of needing surgery"]
[null,"Assess and document on admission, and then daily, the likelihood of needing surgery for people admitted to hospital with acute severe ulcerative colitis. ","1.2.22",2013]
[null,"Be aware that there may be an increased likelihood of needing surgery for people with any of the following:\n•\tstool frequency more than 8 per day\n•\tpyrexia\n•\ttachycardia\n•\tan abdominal X-ray showing colonic dilatation\n•\tlow albumin, low haemoglobin, high platelet count or C-reactive protein (CRP) above 45 mg/litre (bear in mind that normal values may be different in pregnant women).","1.2.23",2013]
[null,"1.3  Information about treatment options for people who are considering surgery"]
[null,"Information when considering surgery"]
[null,"For people with ulcerative colitis who are considering surgery, ensure that a specialist (such as a gastroenterologist or a nurse specialist) gives the person and their family members or carers (as appropriate) information about all available treatment options, and discusses this with them. Information should include the benefits and risks of the different treatments and the potential consequences of no treatment. ","1.3.1",2013]
[null,"Ensure that the person and their family members or carers (as appropriate) have sufficient time and opportunities to think about the options and the implications of the different treatments. ","1.3.2",2013]
[null,"Ensure that a colorectal surgeon gives any person who is considering surgery and their family members or carers (as appropriate) specific information about what they can expect in the short and long term after surgery, and discusses this with them. ","1.3.3",2013]
[null,"Ensure that a specialist (such as a colorectal surgeon, a gastroenterologist, an inflammatory bowel disease nurse specialist or a stoma nurse) gives any person who is considering surgery and their family members or carers (as appropriate) information about: \n•\tdiet\n•\tsensitive topics such as sexual function\n•\teffects on lifestyle\n•\tpsychological wellbeing \n•\tthe type of surgery, the possibility of needing a stoma and stoma care.","1.3.4",2013]
[null,"Ensure that a specialist who is knowledgeable about stomas (such as a stoma nurse or a colorectal surgeon) gives any person who is having surgery and their family members or carers (as appropriate) specific information about the siting, care and management of stomas. ","1.3.5",2013]
[null,"Information after surgery"]
[null,"After surgery, ensure that a specialist who is knowledgeable about stomas (such as a stoma nurse or a colorectal surgeon) gives the person and their family members or carers (as appropriate) information about managing the effects on bowel function. This should be specific to the type of surgery performed (ileostomy or ileoanal pouch) and could include the following:\n•\tstrategies to deal with the impact on their physical, psychological and social wellbeing\n•\twhere to go for help if symptoms occur \n•\tsources of support and advice. ","1.3.6",2013]
[null,"1.4  Maintaining remission in people with ulcerative colitis"]
[null,"Proctitis and proctosigmoiditis"]
[null,"To maintain remission after a mild-to-moderate inflammatory exacerbation of proctitis or proctosigmoiditis, consider the following options, taking into account the person’s preferences:\n•\ta topical aminosalicylate alone (daily or intermittent) or\n•\tan oral aminosalicylate plus a topical aminosalicylate (daily or intermittent) or\n•\tan oral aminosalicylate alone, explaining that this may not be as effective as combined treatment or an intermittent topical aminosalicylate alone. ","1.4.1",2013]
[null,"Left-sided and extensive ulcerative colitis"]
[null,"To maintain remission in adults after a mild-to-moderate inflammatory exacerbation of left-sided or extensive ulcerative colitis:\n•\toffer a low maintenance dose of an oral aminosalicylate \n•\twhen deciding which oral aminosalicylate to use, take into account the person's preferences, side effects and cost. ","1.4.2",2013]
[null,"To maintain remission in children and young people after a mild-to-moderate inflammatory exacerbation of left-sided or extensive ulcerative colitis:\n•\toffer an oral aminosalicylate\n•\twhen deciding which oral aminosalicylate to use, take into account the person's preferences (and those of their parents or carers as appropriate), side effects and cost. ","1.4.3",2013]
[null,"All extents of disease"]
[null,"Consider oral azathioprine or oral mercaptopurine to maintain remission:\n•\tafter 2 or more inflammatory exacerbations in 12 months that require treatment with systemic corticosteroids or\n•\tif remission is not maintained by aminosalicylates. ","1.4.4",2013]
[null,"To maintain remission after a single episode of acute severe ulcerative colitis:\n•\tconsider oral azathioprine or oral mercaptopurine\n•\tconsider oral aminosalicylates if azathioprine and/or mercaptopurine are contraindicated or the person cannot tolerate them. ","1.4.5",2013]
[null,"Dosing regimen for oral aminosalicylates"]
[null,"Consider a once-daily dosing regimen for oral aminosalicylates when used for maintaining remission. Take into account the person’s preferences, and explain that once-daily dosing can be more effective, but may result in more side effects.","1.4.6",2013]
[null,"1.5  Pregnant women"]
[null,"When caring for a pregnant woman with ulcerative colitis:\n•\tEnsure effective communication and information-sharing across specialties (for example, primary care, obstetrics and gynaecology, and gastroenterology).\n•\tGive her information about the potential risks and benefits of medical treatment to induce or maintain remission and of not having treatment, and discuss this with her. Include information relevant to a potential admission for an acute severe inflammatory exacerbation. ","1.5.1",2013]
[null,"1.6   Monitoring"]
[null,"Monitoring bone health"]
[null,"Adults"]
[null,"For recommendations on assessing the risk of fragility fracture in adults, refer to the NICE guideline on osteoporosis: assessing the risk of fragility fracture. ","1.6.1",2013]
[null,"Children and young people"]
[null,"Consider monitoring bone health in children and young people with ulcerative colitis in the following circumstances:\n•\tduring chronic active disease\n•\tafter treatment with systemic corticosteroids\n•\tafter recurrent active disease. ","1.6.2",2013]
[null,"Monitoring growth and pubertal development in children and young people"]
[null,"Monitor the height and body weight of children and young people with ulcerative colitis against expected values on centile charts (and/or z scores) at the following intervals according to disease activity:\n•\tevery 3–6 months: \n-\tif they have an inflammatory exacerbation and are approaching or undergoing puberty or\n-\tif there is chronic active disease or\n-\tif they are being treated with systemic corticosteroids \n•\tevery 6 months during pubertal growth if the disease is inactive\n•\tevery 12 months if none of the criteria above are met. ","1.6.3",2013]
[null,"Monitor pubertal development in young people with ulcerative colitis using the principles of Tanner staging, by asking screening questions and/or carrying out a formal examination. ","1.6.4",2013]
[null,"Consider referral to a secondary care paediatrician for pubertal assessment and investigation of the underlying cause if a young person with ulcerative colitis:\nwith ulcerative colitis:\n•\thas slow pubertal progress or\n•\thas not developed pubertal features appropriate for their age. ","1.6.5",2013]
[null,"Monitoring of growth and pubertal development:\n•\tcan be done in a range of locations (for example, at routine appointments, acute admissions or urgent appointments in primary care, community services or secondary care)\n•\tshould be carried out by appropriately trained healthcare professionals as part of the overall clinical assessment (including disease activity) to help inform the need for timely investigation, referral and/or interventions, particularly during pubertal growth.\nIf the young person prefers self-assessment for monitoring pubertal development, this should be allowed if possible and they should be instructed on how to do this. ","1.6.6",2013]
[null,"Ensure that relevant information about monitoring of growth and pubertal development and about disease activity is shared across services (for example, community, primary, secondary and specialist services). Apply the principles in the NICE guideline on patient experience in adult NHS services in relation to continuity of care. ","1.6.7",2013]